Relapse is a common and complex challenge in substance dependence, driven by alterations in the brain's reward and stress systems. Chronic substance use dysregulates neurotransmitters like dopamine, glutamate, and GABA, leading to cravings and reduced impulse control. Neuroplastic changes in the prefrontal cortex impair decision-making, while the amygdala's heightened sensitivity increases emotional triggers. Stress and environmental cues often act as catalysts for relapse. Pharmacological interventions such as naltrexone, buprenorphine, and anti-craving agents target these mechanisms to prevent relapse. Understanding the neurobiological underpinnings enables the development of personalized treatment plans, combining medication with behavioral therapies to address the root causes and promote long-term abstinence.
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Gangstalking is real, should be studied
Sam Vaknin, Southern Federal University, United Kingdom
Title : Decoding aggression, violence, and substance use in adolescents with conduct disorders: Neurochemical pathways and interventions
Ann Marie Leonard Zabel, Curry College, United States
Title : Sensoria driven genetic decoupling and impaired areal integration in diseases of agency
Denis Larrivee, University of Navarra, Spain
Title : Positive outcome of adherence to the reward deficiency syndrome solution system treatment plan: A longitudinal study
Elizabeth Dale Gilley, The Elle Foundation, United States